Influenza campaign: bridging the gap in vaccination inequity

ISRCTN ISRCTN13441058
DOI https://doi.org/10.1186/ISRCTN13441058
Submission date
23/12/2021
Registration date
13/01/2022
Last edited
13/02/2024
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Respiratory
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Background and study aims:
A campaign to enhance the Influenza vaccination level may help to decrease the burden of disease, not only of Influenza itself, but also of acute cardiovascular diseases.

Understanding the gaps in knowledge, attitude, and practices which may result in vaccination inequity in the Netherlands, especially in different socio-/ethnic groups, are measured using a diagnostic questionnaire at baseline. A video intervention will be shown to the participant, with the aim to improve vaccine confidence and acceptance, and subsequently may result in increasing influenza vaccine coverage. Another aim of the study is to measure the impact of racial/cultural concordance to enhance vaccination confidence and acceptance compared to racial/cultural discordance. To conclude, the aim of this study is to enhance vaccination levels in different socio-economic/ethnic groups.

Who can participate?
Participants are eligible for inclusion if aged 18 years or older.

What does the study involve?
The study consists of a questionnaire and an educational video. Participants will be shown one of four different videos. The video shown to each participant will be shown at random with an equal number of participants being shown each video. These videos are different in content and actors (different ethnicity).

What are the possible benefits and risks of participating?
Participants will help to design evidence-based health care campaigns, tailored to different socio-economic/ethnic groups. There are no anticipated risks of participating.

Where is the study run from?
This study is sponsored by Sanofi (Netherlands) and managed by Amsterdam UMC (Netherlands). The study questionnaire will be run via the internet.

When is the study starting and how long is it expected to run for?
From June 2021 to January 2022

Who is funding the study?
Sanofi (USA)

Who is the main contact?
Professor Dr. Leonard Hofstra
leonard.hofstra@gmail.com

Contact information

Prof Leonard Hofstra
Scientific

De Boelelaan 1117, 1118
Amsterdam
1081HV
Netherlands

ORCiD logoORCID ID 0000-0003-4432-4720
Phone +31644295945
Email leonard.hofstra@gmail.com

Study information

Study designInterventional randomized controlled trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Internet/virtual
Study typePrevention
Participant information sheet 40855_PIS_30Mar20.pdf
Scientific titleA randomised controlIed influenza campaign: improvement of the influenza vaccination confidence and acceptance in different socio-economic and ethnic groups in the Netherlands by different intervention videos using cultural/racial concordance compared to cultural/racial discordance
Study objectives1. A nationwide influenza campaign tailored to different socio-economic/ethnic groups results in improvement of vaccination confidence and tendency to vaccinate (vaccine willingness).
2. Cultural/racial concordance contributes to improvement of vaccination confidence and vaccine willingness compared to cultural/racial discordance.
3. Understanding the gaps in knowledge, attitude and practices which may result in vaccination inequity in the Netherlands, especially in different socio-economic/ethnic groups.
Ethics approval(s)Approved 30/03/2020, Amsterdam UMC Medical Ethics Review Committee (METC) (De Boelelaan 1117, 1118, 1081HV; +31204443394; metc@vumc.nl), ref: 2020.178
Health condition(s) or problem(s) studiedInfluenza
InterventionThis study consists of an educational intervention. The intervention video will be based on a diagnostic survey, which will be conducted in the first phase of this study, where gaps in knowledge, attitude, and practices are measured. In the second phase, participants will fill out a questionnaire, subsequently are randomised to watch one of four different intervention videos, and will then continue with the remainder of the questionnaire. These 4 different intervention videos differ in content and actors (different ethnicity).
Intervention typeBehavioural
Primary outcome measureInfluenza vaccine confidence and acceptance is measured using a questionnaire, before and after showing an intervention video
Secondary outcome measures1. The effect of cultural/racial concordance on vaccination confidence and acceptance is measured using a questionnaire, after showing an intervention video
2. Gaps in knowledge, attitude and practices which may result in vaccination inequity in the Netherlands, especially in different socio-economic/ethnic groups are measured using a diagnostic questionnaire at baseline
Overall study start date22/06/2021
Completion date31/01/2022

Eligibility

Participant type(s)All
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participants4 clusters of 200 participants
Key inclusion criteriaAged ≥18 years
Key exclusion criteriaDoes not meet inclusion criteria
Date of first enrolment01/11/2021
Date of final enrolment31/01/2022

Locations

Countries of recruitment

  • Netherlands

Study participating centre

Amsterdam UMC, locatie VUMC
De Boelelaan 1117, 1118
Amsterdam
1081HV
Netherlands

Sponsor information

Funders

Funder type

Industry

Sanofi
Government organisation / For-profit companies (industry)
Alternative name(s)
sanofi-aventis, Sanofi US, Sanofi-Aventis U.S. LLC, Sanofi U.S.
Location
United States of America

Results and Publications

Intention to publish date31/01/2023
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryData sharing statement to be made available at a later date
Publication and dissemination planPlanned publication in a high-impact peer-reviewed journal
IPD sharing planThe data-sharing plans for the current study are unknown and will be made available at a later date.

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Participant information sheet 30/03/2020 07/01/2022 No Yes
Results article 16/02/2023 13/02/2024 Yes No

Additional files

40855_PIS_30Mar20.pdf

Editorial Notes

13/02/2024: Publication reference added.
07/01/2022: Trial’s existence confirmed by Sanofi.